Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Accumulated Depreciation (2022 - 2025)

Abvc Biopharma (ABVC) has disclosed Accumulated Depreciation for 6 consecutive years, with $3.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Depreciation rose 1.15% year-over-year to $3.4 million, compared with a TTM value of $3.4 million through Dec 2025, up 1.15%, and an annual FY2025 reading of $3.4 million, up 1.15% over the prior year.
  • Accumulated Depreciation was $3.4 million for Q4 2025 at Abvc Biopharma, roughly flat from $3.4 million in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $3.4 million in Q2 2025 and bottomed at $3.3 million in Q1 2024.
  • Average Accumulated Depreciation over 3 years is $3.4 million, with a median of $3.3 million recorded in 2025.
  • The sharpest move saw Accumulated Depreciation increased 0.2% in 2024, then increased 1.83% in 2025.
  • Year by year, Accumulated Depreciation stood at $3.3 million in 2023, then increased by 0.2% to $3.3 million in 2024, then grew by 1.15% to $3.4 million in 2025.
  • Business Quant data shows Accumulated Depreciation for ABVC at $3.4 million in Q4 2025, $3.4 million in Q3 2025, and $3.4 million in Q2 2025.